T. Cyrus

发表

Perfluorocarbon Nanoparticles: A Multidimensional Platform for Targeted Image‐Guided Drug Delivery

S. Caruthers, P. Winter, A. Schmieder, 2011 .

Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy

Shelton D Caruthers, Samuel A Wickline, Gregory M Lanza, 2005, Expert review of cardiovascular therapy.

Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis

G. FitzGerald, D. Praticò, J. Rokach, 2001, Circulation.

A modified provisional stenting approach to coronary bifurcation lesions: clinical application of the "jailed-balloon technique".

R. Bach, J. Lasala, Jeremiah P Depta, 2012, Journal of interventional cardiology.

Use of mechanical assist during high‐risk PCI and STEMI with cardiogenic shock

J. Lasala, T. Cyrus, S. Mathews, 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition.

D. Praticò, T. Cyrus, T. Ding, 2010, Atherosclerosis.

Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice.

D. Rader, J. Witztum, M. Linton, 1999, The Journal of clinical investigation.

12/15-lipoxygenase, oxidative modification of LDL and atherogenesis.

C. Funk, T. Cyrus, 2001, Trends in cardiovascular medicine.

Vitamin E Reduces Progression of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice With Established Vascular Lesions

D. Praticò, J. Rokach, T. Cyrus, 2003, Circulation.

Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro.

H. Darius, M. Buerke, T. Cyrus, 1997, Thrombosis research.

Molecular imaging by cardiovascular MR.

S. Wickline, G. Lanza, T. Cyrus, 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

Abstract 1162: avb3-Integrin-targeted Paramagnetic Nanoparticles Deliver Rapamycin into the Vascular Wall and Inhibit Stenosis Following Balloon Injury

S. Caruthers, T. Harris, T. Williams, 2006 .

Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice

D. Praticò, Lei Zhao, C. Funk, 2002, Circulation.

and Domenico Praticò Deficient Mice − in Low-Density Lipoprotein Receptor Effect of Low-Dose Aspirin on Vascular Inflammation , Plaque Stability , and Atherogenesis

D. Praticò, Lei Zhao, C. Funk, 2002 .

Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.

S. Caruthers, P. Winter, S. Wickline, 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor

D. Praticò, R. Falotico, M. Ma, 2009, British journal of pharmacology.

12/15-Lipoxygenase Gene Disruption Attenuates Atherogenesis in LDL Receptor–Deficient Mice

Lei Zhao, D. Harats, C. Funk, 2001, Circulation.

Selective Interleukin-12 Synthesis Defect in 12/15-Lipoxygenase-deficient Macrophages Associated with Reduced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia*

D. Rader, E. Puré, E. Klein, 2002, The Journal of Biological Chemistry.

Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice.

D. Praticò, J. Dogné, T. Cyrus, 2007, Blood.

Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E—Deficient Mice

D. Rader, G. FitzGerald, D. Praticò, 2001, Circulation.

Nanotechnology in interventional cardiology.

S. Wickline, G. Lanza, T. Cyrus, 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles.

J. Werkmeister, J. Ramshaw, S. Caruthers, 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

thromboxane A2 suppression in LDLR KO mice Thromboxane receptor blockade improves the antiatherogenic effect of

D. Praticò, J. Dogné, T. Cyrus, 2013 .

suppression in LDLR KO mice 2 thromboxane A Thromboxane receptor blockade improves the antiatherogenic effect of

D. Praticò, J. Dogné, T. Cyrus, 2010 .

A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.

D. Praticò, J. Dogné, T. Cyrus, 2007, European journal of pharmacology.

Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin.

D. Praticò, T. Cyrus, Yuemang Yao, 2006, Atherosclerosis.

Involvement of Thromboxane Receptor in the Proatherogenic Effect of Isoprostane F2&agr;-III: Evidence From Apolipoprotein E– and LDL Receptor–Deficient Mice

D. Praticò, T. Cyrus, Yuemang Yao, 2005, Circulation.

Nanomedicine Opportunities in Cardiology

Patrick Winter, Jon Marsh, S. Caruthers, 2006, Annals of the New York Academy of Sciences.

Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis.

G. FitzGerald, D. Praticò, H. Li, 2000, Blood.

Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics

Michael Scott, Trung Tran, Michael Hughes, 2007, International journal of nanomedicine.

Intramural Delivery of Rapamycin With &agr;v&bgr;3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury

Shelton D Caruthers, Samuel A Wickline, Gregory M Lanza, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.

Shelton D Caruthers, Samuel A Wickline, Gregory M Lanza, 2006, Nanomedicine.

Nanoparticles for Magnetic Resonance Imaging of Tumors

S. Caruthers, S. Wickline, G. Lanza, 2007 .

Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents.

Shelton D Caruthers, Samuel A Wickline, Gregory M Lanza, 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

Perfluorocarbon Nanoparticles for Molecular Imaging and Targeted Therapeutics : These particles allow very sensitive detection of the development of conditions such as cancer and heart disease and can be used to diagnose, treat and monitor therapy

J. McCarthy, S. Caruthers, J. Arbeit, 2008 .

Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis

G. FitzGerald, D. Praticò, J. Rokach, 2001, Circulation.

Coronary CT angiography (CCTA) and advances in CT plaque imaging

R. Gropler, P. Woodard, T. Cyrus, 2009, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Intramural Delivery of Rapamycin With &agr;v&bgr;3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury

S. Caruthers, T. Williams, G. Hu, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice.

D. Praticò, J. Dogné, T. Cyrus, 2007, Blood.